Anti-psma antibodies and uses thereof
AssigneeBristol-Myers Squibb Company
InventorsRobert James Hoey, Joshua Carl Goldstein
Life of this patent
Estimating the term…
Abstract
The present application relates to particular anti-PSMA antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies, as well as immunoconjugates comprising the anti-PSMA antibodies.
Claims43
An isolated antibody or antigen-binding portion thereof that specifically binds to PSMA, wherein the antibody or antigen-binding portion thereof comprises:
- (a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence selected from SEQ ID NOs:
- 3-5;
- a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence selected from SEQ ID NOs:
- 6-9;
- a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO:
- 10 or 11;
- a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 12 or 13;
- a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO:
- 14 or 15;
- and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO:
- 16;
- (b) HCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
- 29-32:
- HCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
- 33-36:
- HCDR3 comprising the amino acid sequence of SEQ ID NOs:
- 37 or 38:
- LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 39 or 40:
- LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 41 or 42;
- and LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 43;
- (c) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 48, HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 49:
- HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 50;
- LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 51:
- LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 52;
- and LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 53;
- or
- (d) HCDR1 comprising the amino acid sequence of SEQ ID NO:
- 58:
- HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 59:
- HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 60;
- LCDR1 comprising the amino acid sequence of SEQ ID NO:
- 61:
- LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 62, and LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 63.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An isolated antibody or antigen-binding portion thereof that specifically binds to PSMA, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NOs:
- 3;
- a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NOs:
- 6;
- and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO:
- 10;
- and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 12;
- a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO:
- 14;
- and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.